‘Orphan drugs’ with high price points are being tested as treatments for COVID-19. There’s a better way to spur low-cost innovation for new drugs.
Academic rigor, journalistic flair
Articles on Gilead
Displaying all articles
Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
Preliminary results from a US trial show remdesivir may help in treating COVID-19. But the findings haven’t been peer-reviewed, and the results from other clinical trials have shown little effect.
How much can a multinational take before its social licence to operate in this country expires? How much corporate welfare is too much?
Top contributors
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Professor of Philosophy, Binghamton University, State University of New York
-
Adjunct Associate Professor, School of Social and Political Sciences, University of Sydney
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Lecturer Pharmacy Practice, University of Sydney
